Anti-Müllerian hormone levels in polycystic ovarian syndrome patients with insulin resistance after metformin treatment
10.3760/cma.j.issn.1671-7368.2017.05.013
- VernacularTitle:伴胰岛素抵抗多囊卵巢综合征患者二甲双胍治疗后血清抗苗勒管激素水平的观察
- Author:
Chunxia FANG
;
Qin ZHU
;
Xia LIU
;
Liping WANG
;
Wenwei CAI
;
Weiping FU
- Keywords:
Polycystic ovary syndrome;
Metformin;
Anti-Müllerian hormone
- From:
Chinese Journal of General Practitioners
2017;16(5):388-390
- CountryChina
- Language:Chinese
-
Abstract:
Twenty eight polycystic ovarian syndrome (PCOS) patients complicated with insulin resistance, whose testosterone and luteinizing hormone levels were normal, received metformin treatment (500 mg b.i.d) for 3 months.Blood anti-Müllerian hormone (AMH) levels, endocrine and metabolic parameters were measured before and after treatment.The mean levels of AMH were not significantly changed after 3 months of treatment [(8.4±3.2) vs.(8.5±3.2) μg/L, P=0.148].However, the BMI[(27.6±4.1) vs.(29.3±4.4)kg/m2], fast glucose[(5.32±0.47) vs.(5.55±0.71)mmol/L], fast insulin [(93.3±17.8) vs.(147.7±44.1)pmol/L] and homeostasis model assessment of insulin resistance (HOMA-IR) (3.17±0.71 vs.5.27±1.85) were significantly decreased after treatment (all P<0.05).The results indicate that metformin treatment may not significantly affect serum AMH levels, although it can improve the insulin resistance and reduce the BMI value in PCOS patients.
